IPIX is looking for partnerships after P2's. Our B p2's are all completed for OM, UP/UPS, and ABSSSI. We have had success in ABSSSI and UP/UPS and OM had great interim data that one would find very unlikely to have reversed later in the trial. As such, though there is risk involved, it would have to be expected that very postiive top end data is going to be received in the next few weeks. Major safety issues would have ended the trials just like the Celgene failure noted in your post. Thus, Brilacidin is now looking like a MAJOR platform on which many further indications could be expected to be successful. Not assured, but expected per statements from learned medical members of the IPIX staff.
Prurisol showed great promise in the P2a trial with the 200 dose arm showing that earlier arms were not strong enough so the 300/400 arms should be pretty near the sweet spot for dosing. There could be some safety issues, but since it is a take-off from an already FDA approved drug and there has been no safety stoppage to date even though 70% of patients in the trial were already enrolled by May 2017 I have to think that there has been no major safety issues. Not positive, but I feel the basis is there to expect a positive result in this matter. Thus, I feel there is plenty of data on which to base a positive expectation to the results of this trial.
I think everybody knows nothing is a lock as to success, but I also feel I don't have to be a fence sitter ignoring all positive results to date in coming to a conclusion as to expectations for the trials.
I don't really expect to find medical marvels on a penny stock board, though I know we have a few posters that know their medicine pretty well. I am not one of them, but I appreciate hearing from even the nonprofessionals as long as they provide a basis for their views.
Now those that constantly bash I question as to why they would spend that much time on a stock they obviously don't believe in and thus most likely wouldn't be invested in. Just seems contrary to normal behavior.
Guess we all come to the board with different attitudes.
